8-K: ADC Therapeutics Reports Q3 2024 Financial Results and Provides Operational Update

ADC Therapeutics announced its third quarter 2024 financial results, provided operational updates, and highlighted the discontinuation of the ADCT-601 program.

Summary

• ADC Therapeutics reported a net product revenue of $18.0 million for the third quarter of 2024, and $52.9 million for the first nine months of 2024.
• The company's research and development expenses were $32.5 million for the quarter and $82.5 million for the first nine months of 2024.
• Selling and marketing expenses were $10.7 million for the quarter and $32.8 million for the first nine months of 2024.
• The net loss for the quarter was $44.0 million, or $0.42 per share, and $127.1 million, or $1.35 per share, for the first nine months of 2024.
• Adjusted net loss was $29.4 million, or $0.28 per share, for the quarter and $84.9 million, or $0.90 per share, for the first nine months of 2024.
• The company's cash and cash equivalents were $274.3 million as of September 30, 2024.
• ADC Therapeutics expects full enrollment in the LOTIS-5 trial by the end of 2024 and an interim data update for LOTIS-7 in December 2024.
• The company is discontinuing the ADCT-601 program and prioritizing its exatecan-based platform for solid tumors.
• The company completed an underwritten offering in May 2024, resulting in net proceeds of approximately $97.4 million, extending the expected cash runway into mid-2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to increased revenue, reduced losses, and a clear strategic direction, although the discontinuation of a program and ongoing losses temper the overall outlook.

Positives

• ZYNLONTA product revenue increased compared to the same periods in 2023.
• The company is making progress in its ZYNLONTA trials, with full enrollment expected in LOTIS-5 by year-end.
• The company has a cash runway into mid-2026, providing financial stability.
• The company is prioritizing its exatecan-based platform for solid tumors, which may lead to future growth.
• The company is presenting updated data on ZYNLONTA at a major hematology conference.

Negatives

• The company is discontinuing the ADCT-601 program due to an unfavorable benefit-risk profile.
• The company reported a net loss of $44.0 million for the quarter and $127.1 million for the first nine months of 2024.
• The company's cash and cash equivalents decreased slightly from $278.6 million at the end of 2023 to $274.3 million as of September 30, 2024.

Risks

• The discontinuation of the ADCT-601 program may impact the company's pipeline and future growth.
• The company's continued losses may raise concerns about its long-term financial sustainability.
• The company's success is dependent on the continued development and commercialization of ZYNLONTA and other ADC candidates.
• The company faces risks related to clinical trial outcomes, regulatory approvals, and market competition.

Future Outlook

The company expects full enrollment in the LOTIS-5 trial by the end of 2024, an interim data update for LOTIS-7 in December 2024, and a data update from the Phase 3 confirmatory trial in late 2025. The company also plans to advance its exatecan-based programs for ADCs targeting Claudin-6, PSMA and NaPi2b.

Management Comments

• Ameet Mallik, Chief Executive Officer of ADC Therapeutics, stated that they are excited about the advancements in their ZYNLONTA trials and look forward to reporting more on the combination with glofitamab in the LOTIS-7 trial.
• Ameet Mallik also mentioned that they are discontinuing ADCT-601 and will prioritize their exatecan-based platform for solid tumors.
• He also stated that with their expected cash runway into mid-2026, they believe they are well positioned to execute their strategy and advance multiple value-generating catalysts going forward.

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly in the field of antibody-drug conjugates (ADCs). The discontinuation of ADCT-601 and the prioritization of the exatecan-based platform reflect a strategic shift in the company's focus. The progress in ZYNLONTA trials and the upcoming data presentations are important for the competitive landscape in lymphoma treatment.

Comparison to Industry Standards

• ADC Therapeutics' ZYNLONTA competes with other lymphoma treatments such as CAR-T therapies and other antibody-drug conjugates.
• The company's reported revenue of $18.0 million for the quarter is a key metric to compare against competitors in the ADC space, such as Seagen and ImmunoGen.
• The decision to discontinue ADCT-601 is similar to other companies that have had to make strategic decisions to focus on more promising programs.
• The company's cash runway into mid-2026 is a positive sign compared to other biotech companies that may face near-term funding challenges.
• The company's focus on exatecan-based ADCs is in line with the industry trend of exploring novel payloads for ADCs.

Stakeholder Impact

• Shareholders may be encouraged by the increased revenue and reduced losses, but concerned about the discontinuation of the ADCT-601 program.
• Employees may be affected by the prioritization of certain programs and the discontinuation of others.
• Patients may benefit from the continued development of ZYNLONTA and other ADC candidates.
• Creditors may be reassured by the company's extended cash runway.

Next Steps

• The company will continue enrollment in the LOTIS-7 trial and provide an interim data update in December 2024.
• The company will present updated ZYNLONTA data at the American Society of Hematology Annual Meeting in December 2024.
• The company will continue to advance its exatecan-based programs for ADCs targeting Claudin-6, PSMA and NaPi2b.
• The company will select one target to move toward IND which is expected to be disclosed in 2025.

Key Dates

Keywords

ADC Therapeutics, ZYNLONTA, Antibody Drug Conjugates, ADCT-601, LOTIS-5, LOTIS-7, Hematologic Malignancies, Solid Tumors, Financial Results, Clinical Trials